Oral Solid Dosage Manufacturing Market

研究執行與發布：Roots Analysis　·　發布日期 2026-08-17　·　181 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

出版商 Roots Analysis 產業別 Healthcare & Life Sciences出版日期 2026-08-17頁數 181報告編號 RA100424

授權報價

Single User	$4,799 USD
Multi User	$7,999 USD
Enterprise / Global Site Licence	$17,999 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Oral Solid Dosage Manufacturing Market (2nd Edition) by Type of Finished Dosage Form, Type of Packaging, Company Size, Type of Release Mechanism, Therapeutic Area and Geographical Regions - Trends and Forecast Till 2035

報告摘要

ORAL SOLID DOSAGE MANUFACTURING MARKET: OVERVIEW As per Roots Analysis, the global oral solid dosage manufacturing market is estimated to grow from USD 623 billion in the current year to USD 861 billion by 2035, at a CAGR of 3.7% during the forecast period, till 2035. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS Over the past several years, the increasing complexity of active pharmaceutical ingredients (APIs) has driven the development of a wide range of novel formulations designed to enhance targeted drug delivery. Despite these advancements, oral solid dosage (OSD) forms, including tablets and capsules, continue to maintain a dominant position in the global pharmaceutical market. Notably, more than two-thirds of all prescribed medications worldwide are administered in the form of oral solid dosages. This widespread adoption can be attributed to their inherent advantages, including cost-effectiveness, improved patient convenience, and greater stability, all of which contribute to enhanced medication adherence. Driven by continuous innovation, drug developers are increasingly focusing on advanced oral formulations, such as orally disintegrating tablets (ODTs), drug-device combination products, and sustained-release dosage forms, to address challenges related to API solubility and bioavailability. However, the manufacturing of oral solid dosage forms, particularly those incorporating highly potent APIs remains a complex and research-intensive process. It requires specialized expertise across multiple stages, from formulation development to commercial-scale production. Consequently, in order to meet rising demand and overcome operational challenges, including formulation complexity, stringent regulatory requirements, and supply chain constraints, drug developers are increasingly partnering with specialized contract service providers. Going forward, continued outsourcing trends and advancements in formulation technologies are expected to drive sustained growth and innovation within the oral solid dosage CDMO market. Growth Drivers: Strategic Enablers of Market Expansion The increasing emergence of virtual pharmaceutical companies is playing a pivotal role in driving growth within the oral solid dosage (OSD) manufacturing market. These organizations adopt an asset-light operating model by outsourcing critical functions, including formulation development, manufacturing, and analytical testing, to specialized partners. This approach enables faster development timelines, enhanced operational flexibility, and reduced capital expenditure. As a result, contract development and manufacturing organizations (CDMOs) are experiencing a significant uptick in demand, particularly for their expertise in tablet and capsule production. In addition, the market is witnessing robust growth driven by rising demand for advanced and innovative oral solid formulations. Patients and healthcare providers are increasingly demanding dosage forms that provide enhanced bioavailability, controlled release, and easier administration. This has driven growing interest in advanced technologies such as digital pills, 3D-printed tablets, and amorphous solid dispersions. In response, pharmaceutical companies are actively investing in cutting-edge formulation and manufacturing capabilities to address evolving therapeutic needs and maintain competitive advantage. Market Challenges: Critical Barriers Impeding Progress The oral solid dosage (OSD) manufacturing market is characterized by intense competition, driven by the entry of new players equipped with advanced formulation and manufacturing capabilities. This competitive landscape is further shaped by evolving regulatory requirements, pricing pressures, and shifting expectations from patients and healthcare stakeholders. In this dynamic environment, companies must continuously adapt their strategies and capabilities to sustain competitiveness and achieve long-term growth. At the same time, ensuring product stability remains a critical challenge for service providers. Factors such as moisture sensitivity, temperature variability, and formulation complexity can significantly impact product integrity and performance. To address these concerns, companies are required to develop robust formulations that ensure extended shelf life and consistent therapeutic efficacy. Additionally, challenges related to scale-up, process validation, and variability in manufacturing equipment further complicates operations. Successfully navigating these issues necessitates the integration of advanced technical expertise, tightly controlled manufacturing environments, and rigorous quality control frameworks to ensure batch-to-batch consistency and compliance with stringent regulatory standards. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: KEY INSIGHTS The report delves into the current state of the oral solid dosage contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include: 1. Presently, over 720 companies claim to have the required expertise to offer manufacturing services for a broad spectrum of oral solid dosage forms, including modified release formulations of tablets and capsules. 2. 80% of players operate as integrated service providers, offering end-to-end capabilities from early-stage development to oral solid dosage packaging, thereby streamlining supplier management for sponsor players. 3. Owing to the rise in demand for complex oral solid formulations, the need for drug innovators is evolving; as a result, service providers are upgrading their technical capabilities to cater to customized requests of their clients. 4. Driven by the growing demand for oral solids, CDMOs have made considerable investments to expand their existing capacities and capabilities; this trend is most pronounced in Europe. 5. The global oral solid dosage manufacturing capacity is well distributed across various geographies; interestingly, around 90% of the total installed capacity is available in facilities operating at commercial scale. 6. Given the growing pipeline of oral solid dosage products, the demand for oral solid contract manufacturing services is expected to expand steadily over the next decade. 7. Ongoing advancements in OSD manufacturing techniques have proven useful in meeting the global demand across several regions; these are anticipated to drive the overall market at a steady pace in future. 8. With growing demand for easy to administer and patient centric drugs, the oral solid dosage manufacturing market is likely to grow at a steady CAGR over the next decade. 9. North America is expected to capture a significant market share of the overall oral solid dosage manufacturing market in the near future. 10. Driven by rapid technological advancements in OSD manufacturing by prominent US players, this market is poised for strong growth, supported by rising demand for high-quality and efficient oral dosage solutions. Oral Solid Dosage Manufacturing Market The market sizing and opportunity analysis has been segmented across the following parameters: Type of Finished Dosage Form • Tablets • Capsules • Others Type of Packaging • Bottles • Blisters • Others By Type of Release Mechanism • Immediate Release • Modified Release Scale of Operation • Pre-commercial • Commercial Therapeutic Area • Oncological Disorders • Cardiovascular Disorders • Infectious Diseases • Neurological Disorders • Diabetes • Respiratory Disorders • Immunological Disorders • Genetic Disorders • Rare Diseases • Others Company Size • Small • Mid-sized • Large Key Geographical Regions • North America • Europe • Asia-Pacific • Latin America • Middle East and North Africa ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: KEY SEGMENTS Which Finished Dosage Form Account for the Largest Share of Oral Solids Market? By 2035, the tablets segment is projected to account for the largest share (~75%) of the oral solid dosage (OSD) manufacturing market, while also exhibiting steady growth over the forecast period. This dominance can be attributed to the inherent advantages of tablets, including lower manufacturing costs, extended shelf life, and ease of large-scale production. Additionally, the availability of diverse delivery formats such as extended-release and delayed-release formulations further enhances their therapeutic applicability and market potential. Company Size Analysis: Large Companies Dominate While Emerging Firms Accelerate Market Expansion The global market is segmented based on company size into small, mid-sized, and large organizations. Among these, large companies are expected to hold the majority share (~75%) of the market by 2035. Their leadership position is supported by access to advanced manufacturing infrastructure, significant capital investments, and established expertise in navigating complex regulatory pathways. Conversely, small companies are anticipated to register a higher compound annual growth rate (CAGR) during the forecast period. This growth is primarily driven by their increasing reliance on contract development and manufacturing organizations (CDMOs), owing to limited in-house production capabilities. Strategic collaborations with CDMOs enable these firms to streamline development timelines, optimize costs, and access specialized technical expertise. Regional Analysis: North America Leading, Europe Emerging as a High-Growth Market North America is expected to dominate the oral solid dosage manufacturing market, capturing approximately 50% of the global share by 2035. This can be attributed to strong commercial demand for oral solid pharmaceuticals in the United States, along with the presence of well-established manufacturing players. Furthermore, leading companies in the region have been actively expanding their production capacities and technological capabilities to address increasing market demand. In contrast, Europe is projected to witness the fastest growth over the forecast period. This growth is driven by rising investments in research and development of novel therapeutics, as well as stringent regulatory standards that favor specialized and high-quality manufacturing providers. Additionally, the increasing demand for generic drugs fueled by patent expirations and the pharmaceutical industry’s growing reliance on CDMOs for cost efficiency and technical expertise, is further accelerating market expansion in the region. Example Players in the Oral Solid Dosage Contract Manufacturing Market • Aenova • Alcami • Almac • Cambrex • Catalent • CMIC • Contract Pharmacal • Delpharm • Hetero Drugs • Madras Pharmaceuticals • Micro Labs • Recipharm Industry Experts on Oral Solid Dosage Manufacturing Market The oral solid dosage contract manufacturing market report includes detailed transcripts of interviews conducted with the following individuals: • Senior Executive Director, Global Sales & Marketing, Large Company, Japan • Vice President, Mid-Sized Company, Sweden • Senior Vice President, Mid-Sized Company, US • Chief Scientific Officer, Mid-Sized Company, Finland • Senior Management, Scientific Marketing, Very Large Company, US • Director of Formulation and Development, Mid-Sized Company, Georgia • Senior Vice President, Large Company, US ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the oral solid dosage contract manufacturing market, focusing on key market segments, including [A] type of finished dosage form, [B] type of packaging, [C] company size, [D] type of release mechanism, [E] therapeutic area and [F] geographical regions. • Market Landscape: A comprehensive evaluation of companies offering contract services for oral solid dosage form, considering various parameters, such as [A] year of establishment, [B] company size (in terms of the number of employees), [C] location of headquarters, [D] company ownership, [E] type of service offered, [F] type of finished dosage forms manufactured, [G] type of packaging offered, [H] scales of operation and [I] additional manufacturing capabilities. • Company Competitiveness Analysis: A comprehensive competitive analysis of oral solid dosage contract manufacturing service providers, examining factors, such as [A] supplier strength and [B] service strength. • Regional Capability Analysis: A comprehensive regional capability assessment framework the oral solid dosage contract manufacturers that evaluates key geographies by various parameters, including [A] type of services offered, [B] type of finished dosage forms manufactured, [C] type of packaging offered, [D] scales of operation and [E] location of manufacturing facilities of the service providers. • Company Profiles: In-depth profiles of key oral solid dosage contract manufacturers, focusing on [A] company overviews, [B] financial information (if available), [C] oral solid dosage service portfolio, [D] manufacturing capabilities and facilities, [E] recent developments and [F] an informed future outlook. • Make Versus Buy Decision Framework: An insightful framework that emphasizes the key indicators and factors that need to be considered by oral solid dosage drug developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers. • Recent Expansions: An examination of the different expansion efforts made by service providers in this field to enhance their manufacturing capabilities. This analysis considers various factors, including the [A] year of expansion, [B] purpose of expansion, [C] type of an estimate of the global installed capacity (in terms of number of oral solid units and volume of API) for the manufacturing of oral solids, based on information provided by various industry stakeholders in the public domain. It also features the distribution of the available capacity on the basis of [D] company size, [E] scale of operation, [F] type of finished dosage form and [G] key geographical regions. Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand. • Demand Analysis: Informed estimates of the annual commercial and clinical demand for oral solid doses based on several relevant parameters, such as [A] key geographical regions and [B] therapeutic areas. • Total Cost of Ownership: A detailed analysis of the total cost of ownership for an oral solid dosage contract manufacturing service provider, highlighting the expenses associated with the establishment and maintenance of an oral solid dosage manufacturing facility, over a period of 20 years. • Regulatory Landscape: A discussion on general regulatory guidelines laid down by major regulatory bodies across different countries, featuring an elaborative assessment of several CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies. • Case Study 1: A general discussion on taste masking service providers for oral solids, providing information on [A] scale of operation, [B] manufacturing scalability, other services offered along with information on [C] type of formulation, [D] end users, [E] techniques used for taste masking, [F] branch of healthcare and [G] regional capability. Further, the chapter includes the current market landscape of taste masking technology providers, providing information on [H] technology name, [I] techniques used, [J] type of finished dosage form, [K] end users along with information on patent, availability of technology for partnerships and licensing. In addition, the chapter provides details on the [L] year of establishment, [M] company size and [N] location of headquarters. • Case Study 2: A general discussion on drug bioavailability enhancement service providers for oral solids, based on several relevant parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] bioavailability enhancement principle supported, [E] bioavailability enhancement approach employed, including [E1] solid dispersion, [E2] size reduction, [E3] lipid-based, and [E4] other bioavailability enhancement approaches, [F] type of dosage form supported (solids, fine particles and semi-solids). KEY QUESTIONS ANSWERED IN THIS REPORT • Which are the leading companies in the oral solid dosage manufacturing market? • Which region dominates the oral solid dosage manufacturing market? • What are the key trends observed in the oral solid dosage manufacturing market? • What factors are likely to influence the evolution of this market? • What are the primary challenges faced by oral solid dosage manufacturers? • What is the current and future market size? • What is the CAGR of this market? • How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing. • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively. • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies. • The report allows for more effective communication with the audience and in building strong business relations. ADDITIONAL BENEFITS • Complimentary PPT Insights Packs • Complimentary Excel Data Packs for all Analytical Modules in the Report • 10% Free Content Customization • Detailed Report Walkthrough Session with Research Team • Free Updated report if the report is 6-12 months old or older

目錄 Table of Contents

1. PREFACE 1.1. Scope of the Report 1.2. Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. RESEARCH METHODOLOGY 2.1. Chapter Overview 2.2. Research Assumptions 2.3. Database Building 2.4. Project Methodology 2.5. Robust Quality Control 3. MARKET DYNAMICS 3.1. Chapter Overview 3.3. Market Assessment Framework 3.4. Forecasting Tools and Techniques 3.5. Key Considerations 3.6. Limitations 4. MACRO-ECONOMIC INDICATORS 4.1. Chapter Overview 4.2. Market Dynamics 4.3. Concluding Remarks 5. EXECUTIVE SUMMARY 5.1. Executive Summary: Market Landcape 5.2. Executive Summary: Recent Expansions 5.3. Executive Summary: Capability Analysis 5.4. Executive Summary: Demand Analysis 6. INTRODUCTION 6.1. Chapter Overview 6.2. Types of Dosage Forms 6.3 Overview of Oral Solid Dosage Forms 6.3.1. Components of Oral Solid Dosage Forms 6.3.2. Classification of Oral Solid Dosage Forms 6.3.3. Manufacturing of Oral Solid Dosage Forms 6.3.4. Emerging Trends in Oral Solid Dosage Manufacturing 6.4. Overview of Oral Solid Contract Manufacturing 6.4.1. Services Offered by CMOs and CDMOs for Oral Solid Dosage 6.4.2. Key Considerations while Selecting a CDMO Partner 6.4.3. Risks and Challenges Associated with Outsourcing Oral Solid Dosage Manufacturing Operations 6.5. Future Perspectives 7. ORAL SOLID DOSAGE MANUFACTURING ORGANIZATIONS (CMOs): MARKET LANDSCAPE 7.1. Chapter Overview 7.2. Oral Solid Dosage CMOs: Overall Market Landscape 7.2.1. Analysis by Year of Establishment 7.2.2. Analysis by Company Size 7.2.3. Analysis by Location of Headquarters 7.2.4. Analysis by Location of Manufacturing Facility 7.2.5. Analysis by Company Ownership 7.2.6. Analysis by Type of Service Provider 7.2.7. Analysis by Type of Business Segment 7.2.8. Analysis by Service Offered 7.2.9. Analysis by Company Size and Service Offered 7.2.10. Analysis by Location of Headquarters and Service Offered 7.2.11. Analysis by Year of Establishment, Location of Headquarters and Service Offered 7.2.12. Analysis by Type of Oral Dosage Form Manufactured 7.2.13. Analysis by Type of Packaging Offered 7.2.14. Analysis by Scale of Operation 7.2.15. Analysis by Additional Manufacturing Capabilities 7.2.15.1. Availability of Continuous Oral Solid Dosage Manufacturing 7.2.15.2. Availability of Highly Potent Oral Solid Dosage Manufacturing 7.2.16. Analysis by Type of Business Segment and Scale of Operation 7.2.17. Analysis by Service Offered and Scale of Operation 7.2.18. Analysis by Type of Packaging Offered and Scale of Operation 7.2.19. Leading Players: Analysis by Number of Manufacturing Facilities 8. COMPANY COMPETITIVENESS ANALYSIS 8.1. Chapter Overview 8.2. Assumptions / Key Parameters 8.3. Methodology 8.4. Company Competitiveness Analysis: Oral Solid Dosage Manufacturers based in North America 8.5. Company Competitiveness Analysis: Oral Solid Dosage Manufacturers based in Europe 8.6. Company Competitiveness Analysis: Oral Solid Dosage Manufacturers based in Asia-Pacific and Rest of the World 8.7. Company Competitiveness Analysis: Benchmarking the Capabilities of Leading Players 9. REGIONAL CAPABILITY ANALYSIS 9.1. Chapter Overview 9.2. Key Assumptions and Methodology 9.3. Oral Solid Dosage Manufacturing Capabilities in North America 9.4. Oral Solid Dosage Capabilities in Europe 9.5. Oral Solid Dosage Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World 9.6. Concluding Remarks 10. COMPANY PROFILES 10.1. Chapter Overview 10.2. Alcami 10.2.1. Company Overview 10.2.2. Financial Information 10.2.3. Oral Solid Dosages Portfolio 10.2.4. Recent Developments and Future Outlook 10.3. Cambrex 10.4. Catalent 10.5. CMIC 10.6. Contract Pharmacal 10.7. Aenova 10.8. Almac 10.9. Delpharm 10.10. Hetero Drugs 10.11. Micro Lab 10.12. Recipharm 11. MAKE VERSUS BUY DECISION FRAMEWORK 11.1. Chapter Overview 11.2. Assumptions and Key Parameters 11.3. Oral Solid Dosage Manufacturing: Make versus Buy Decision Making 11.3.1. Scenario 1 11.3.2. Scenario 2 11.3.3. Scenario 3 11.3.4. Scenario 4 11.4. Concluding Remarks 12. RECENT EXPANSIONS 12.1. Chapter Overview 12.2. Oral Solid Dosage Manufacturing: List of Expansions 12.2.1. Analysis by Year of Expansion 12.2.2. Analysis by Purpose of Expansion 12.2.3. Analysis by Year and Purpose of Expansion 12.2.4. Analysis by Type of Oral Solid Dosage Form Manufactured 12.2.5. Analysis by Purpose of Expansion and Type of Oral Solid Dosage Form Manufactured 12.2.6. Analysis by Location of Expanded Facility 12.2.7. Analysis by Purpose of Expansion and Location of Expanded Facility 12.2.8. Most Active Players: Analysis by Number of Recent Expansions 13. CAPACITY ANALYSIS 13.1. Chapter Overview 13.2. Key Assumptions and Methodology 13.2.1. Oral Solid Dosage Manufacturing: Global Installed Capacity (by Number of Doses) 13.2.1.1. Analysis by Company Size 13.2.1.2. Analysis by Scale of Operation 13.2.1.3. Analysis by Type of Formulation 13.2.1.4. Analysis by Location of Manufacturing Facility 13.2.1.5. Analysis by Company Size and Location of Manufacturing Facility 13.2.1.6. Analysis by Scale of Operation and Location of Manufacturing Facility 13.2.1.7. Analysis by Type of Formulation and Location of Manufacturing Facility 13.2.2. Oral Solid Dosage Manufacturing: Global Installed Capacity (by Volume of Doses) 13.2.2.1. Analysis by Company Size 13.2.2.2. Analysis by Scale of Operation 13.2.2.3. Analysis by Type of Formulation 13.2.2.4. Analysis by Location of Manufacturing Facility 13.2.2.5. Analysis by Company Size and Location of Manufacturing Facility 13.2.2.6. Analysis by Scale of Operation and Location of Manufacturing Facility 13.2.2.7. Analysis by Type of Formulation and Location of Manufacturing Facility 13.2.3. Oral Solid Dosage Manufacturing: Global Installed Capacity (by Facility Area) 13.2.3.1. Analysis by Company Size 13.2.3.2. Analysis by Scale of Operation 13.2.3.3. Analysis by Location of Manufacturing Facility 13.2.3.4. Analysis by Company Size and Location of Manufacturing Facility 13.2.3.5. Analysis by Scale of Operation and Location of Manufacturing Facility 13.3. Concluding Remarks 14. DEMAND ANALYSIS 14.1. Chapter Overview 14.2. Key Assumptions and Methodology 14.3. Overall Demand for Oral Solid Dosage Forms, till 2035 14.4. Overall Commercial Demand for Oral Solid Dosage, till 2035 14.4.1. Commercial Demand for Oral Solid Dosage: Analysis by Geography 14.4.1.1. Commercial Demand for Oral Solid Dosage in North America, till 2035 14.4.1.2. Commercial Demand for Oral Solid Dosage in Europe, till 2035 14.4.1.3. Commercial Demand for Oral Solid Dosage in Asia-Pacific and Rest of the World, till 2035 14.4.2. Commercial Demand for Oral Solid Dosage: Distribution by Therapeutic Area 14.4.2.1. Commercial Demand for Oral Solid Dosage for Oncological Disorders, till 2035 14.4.2.2. Commercial Demand for Oral Solid Dosage for Neurological Disorders, till 2035 14.4.2.3. Commercial Demand for Oral Solid Dosage for Cardiovascular Disorders, till 2035 14.4.2.4. Commercial Demand for Oral Solid Dosage for Infectious Diseases, till 2035 14.4.2.5. Commercial Demand for Oral Solid Dosage for Metabolic Disorders, till 2035 14.4.2.6. Commercial Demand for Oral Solid Dosage for Respiratory Disorders, till 2035 14.4.2.7. Commercial Demand for Oral Solid Dosage for Immunological Disorders, till 2035 14.4.2.8. Commercial Demand for Oral Solid Dosage for Genetic Disorders, till 2035 14.4.2.9. Commercial Demand for Oral Solid Dosage for Gastrointestinal Disorders, till 2035 14.4.2.10. Commercial Demand for Oral Solid Dosage for Other Disorders, till 2035 14.5. Overall Clinical Demand for Oral Solid Dosage, till 2035 14.5.1. Clinical Demand for Oral Solid Dosage: Analysis by Phase of Trial 14.5.1.1. Clinical Demand for Oral Solid Dosage in Phase I Trials, till 2035 14.5.1.2. Clinical Demand for Oral Solid Dosage in Phase II Trials, till 2035 14.5.1.3. Clinical Demand for Oral Solid Dosage in Phase III Trials, till 2035 14.6. Demand and Supply Analysis 15. TOTAL COST OF OWNERSHIP FOR ORAL SOLID DOSAGE MANUFACTURING ORGANIZATIONS 15.1. Chapter Overview 15.2. Key Parameters 15.3. Assumptions and Methodology 15.4. Sample Dataset for the Estimation of Total Cost of Ownership 15.5. Total Cost of Ownership for Oral Solid Dosage Manufacturing Organizations, Y0-Y20 15.6. Total Cost of Ownership for Oral Solid Dosage Manufacturing Organizations: Analysis by CapEx and OpEx, Y0 and Y20 15.6.1. Total Cost of Ownership for Oral Solid Manufacturing Organizations: Analysis by CapEx, Y0 15.6.2. Total Cost of Ownership for Oral Solid Dosage Manufacturing Organizations: Analysis by OpEx, Y1-Y20 15.7. Concluding Remarks 16. REGULATORY LANDSCAPE FOR ORAL SOLID DOSAGE MANUFACTURERS 16.1. Chapter Overview 16.2. Regulatory Guidelines in North America 16.2.1. The US Scenario 16.2.2. Canadian Scenario 16.3. Regulatory Guidelines in Europe 16.4. Regulatory Guidelines in Asia-Pacific and Rest of the World 16.4.1. Chinese Scenario 16.4.2. Indian Scenario 16.4.3. Japanese Scenario 16.4.4. South Korean Scenario 16.4.5 Australian Scenario 16.4.6. Brazilian Scenario 16.5. Oral Solid Dosage CMOs: Information on Approvals from Various Regulatory Authorities 16.6. Bubble Analysis: Regional Regulatory Summary 17. TASTE MASKING SERVICE PROVIDERS: MARKET LANDSCAPE 17.1. Chapter Overview 17.2. Taste Masking Service Providers 17.2.1. Analysis by Year of Establishment 17.2.2. Analysis by Company Size 17.2.3. Analysis by Location of Headquarters 17.2.4. Analysis by Year of Establishment and Location of Headquarters 17.2.5. Analysis by Company Size and Location of Headquarters 17.3. Taste Masking Services: Overall Market Landscape 17.3.1. Analysis by Service Offered 17.3.2. Analysis by Scale of Operation 17.3.3. Analysis by Other Service Offered 17.3.4. Analysis by Type of Formulation 17.3.5. Analysis by End Users 17.3.6. Analysis by Techniques Used for Taste Masking 17.3.7. Analysis by Branch of Healthcare 17.3.8. Analysis by Regional Capability 17.4. Taste Masking Technologies: Overall Market Landscape 17.4.1. Analysis by Service Offered 17.4.2. Analysis by Techniques Used 17.4.3. Analysis by Type of Formulation 17.4.4. Analysis by End Users 17.5. Taste Masking Technology Providers 17.5.1. Analysis by Year of Establishment 17.5.2. Analysis by Company Size 17.5.3. Analysis by Location of Headquarters 17.5.4. Analysis by Year of Establishment and Location of Headquarters 17.5.5. Analysis by Company Size and Location of Headquarters 17.5.6. Leading Players: Analysis by Number of Technologies 18. BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES 18.1. Chapter Overview 18.2. Bioavailability Enhancement Technologies: Technology Providers Landscape 18.2.1. Analysis by Year of Establishment 18.2.2. Analysis by Company Size 18.2.3. Analysis by Location of Headquarters 18.2.4. Analysis by Company Size and Location of Headquarters 18.2.5. Leading Players: Analysis by Number of Technologies 18.3. Bioavailability Enhancement Technologies: Market Landscape 18.3.1. Analysis by Bioavailability Enhancement Principle 18.3.2. Analysis by Bioavailability Enhancement Approach 18.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach 18.3.4. Analysis by Type of Molecule 18.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule 18.3.6. Analysis by Route of Administration 18.3.7. Analysis by Availability for License 18.3.8. Analysis by Intellectual Property Rights 19. MARKET IMPACT ANALYSIS 19.1. Market Drivers 19.2. Market Restraints 19.3. Market Opportunities 19.4. Market Challenges 20. GLOBAL ORAL SOLID DOSAGE MANUFACTURING MARKET 20.1. Key Assumptions 20.2. Forecast Methodology 20.3. Global Oral Solid Dosage Manufacturing Market, Till 2035 20.3.1. Multivariate Scenario Analysis 20.3.1.1. Conservative Scenario 20.3.1.2. Optimistic Scenario 20.5. Key Market Segmentations 21. ORAL SOLID DOSAGE MANUFACTURING MARKET, BY TYPE OF FINISHED DOSAGE FORM 21.1. Oral Solid Dosage Manufacturing Market: Distribution by Type of Finished Dosage Form 21.1.1. Oral Solid Dosage Manufacturing Market for Tablets, Forecasted Estimates (Till 2035) 21.1.2. Oral Solid Dosage Manufacturing Market for Capsules, Forecasted Estimates (Till 2035) 21.1.3. Oral Solid Dosage Manufacturing Market for Other Finished Dosage Forms, Forecasted Estimates (Till 2035) 21.2. Data Triangulation and Validation 22. ORAL SOLID DOSAGE MANUFACTURING MARKET, BY TYPE OF PACKAGING 22.1. Oral Solid Dosage Manufacturing Market: Distribution by Type of Packaging 22.1.1. Oral Solid Dosage Manufacturing Market for Blisters, Forecasted Estimates (Till 2035) 22.1.2. Oral Solid Dosage Manufacturing Market for Bottles, Forecasted Estimates (Till 2035) 22.1.3. Oral Solid Dosage Manufacturing Market for Other Packaging, Forecasted Estimates (Till 2035) 22.2. Data Triangulation and Validation 23. ORAL SOLID DOSAGE MANUFACTURING MARKET, BY TYPE OF RELEASE MECHANISM 23.1. Oral Solid Dosage Manufacturing Market: Distribution by Type of Release Mechanism 23.1.1. Oral Solid Dosage Manufacturing Market for Immediate Release, Forecasted Estimates (Till 2035) 23.1.2. Oral Solid Dosage Manufacturing Market for Modified Release, Forecasted Estimates (Till 2035) 23.2. Data Triangulation and Validation 24. ORAL SOLID DOSAGE MANUFACTURING MARKET, BY THERAPEUTIC AREA 24.1. Oral Solid Dosage Manufacturing Market: Distribution by Type of Release Mechanism 24.1.1. Oral Solid Dosage Manufacturing Market for Oncological Disorders, Forecasted Estimates (Till 2035) 24.1.2. Oral Solid Dosage Manufacturing Market for Cardiovascular Disorders, Forecasted Estimates (Till 2035) 24.1.3. Oral Solid Dosage Manufacturing Market for Infectious Diseases, Forecasted Estimates (Till 2035) 24.1.4. Oral Solid Dosage Manufacturing Market for Neurological Disorders, Forecasted Estimates (Till 2035) 24.1.5. Oral Solid Dosage Manufacturing Market for Diabetes, Forecasted Estimates (Till 2035) 24.1.6. Oral Solid Dosage Manufacturing Market for Respiratory Disorders, Forecasted Estimates (Till 2035) 24.1.7. Oral Solid Dosage Manufacturing Market for Immunological Disorders, Forecasted Estimates (Till 2035) 24.1.8. Oral Solid Dosage Manufacturing Market for Genetic Disorders, Forecasted Estimates (Till 2035) 24.1.9. Oral Solid Dosage Manufacturing Market for Rare Diseases, Forecasted Estimates (Till 2035) 24.1.10. Oral Solid Dosage Manufacturing Market for Other Disorders, Forecasted Estimates (Till 2035) 25. ORAL SOLID DOSAGE MANUFACTURING MARKET, BY COMPANY SIZE 25.1. Oral Solid Dosage Manufacturing Market: Distribution by Type of Company Size 25.1.1. Oral Solid Dosage Manufacturing Market for Small Companies, Forecasted Estimates (Till 2035) 25.1.2. Oral Solid Dosage Manufacturing Market for Mid-Sized Companies, Forecasted Estimates (Till 2035) 25.1.3. Oral Solid Dosage Manufacturing Market for Large Companies, Forecasted Estimates (Till 2035) 26. ORAL SOLID DOSAGE MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS 26.1. Oral Solid Dosage Manufacturing Market: Distribution by Geographical Regions 26.1.1. Oral Solid Dosage Manufacturing Market in North America, Forecasted Estimates (Till 2035) 26.1.2. Oral Solid Dosage Manufacturing Market in Europe, Forecasted Estimates (Till 2035) 26.1.3. Oral Solid Dosage Manufacturing Market in Aisa-Pacific, Forecasted Estimates (Till 2035) 26.1.4. Oral Solid Dosage Manufacturing Market in Latin America, Forecasted Estimates (Till 2035) 26.1.5. Oral Solid Dosage Manufacturing Market in Middle East and North Africa, Forecasted Estimates (Till 2035) 26.2. Market Dynamics Assessment 26.3.1. Market Movement Analysis 26.3.2. Penetration-Growth (P-G) Matrix 26.4. Data Triangulation and Validation 27. MARKET FORECAST OPPORTUNITY ANALYSIS: NORTH AMERICA 27.1. Oral Solid Dosage Manufacturing Market in North America: Distribution by Type of Finished Dosage Forms 27.1.1. Oral Solid Dosage Manufacturing Market in North America for Tablets, Forecasted Estimates (Till 2035) 27.1.2. Oral Solid Dosage Manufacturing Market in North America for Capsules, Forecasted Estimates (Till 2035) 27.1.3. Oral Solid Dosage Manufacturing Market in North America for Other Finished Dosage Forms, Forecasted Estimates (Till 2035) 27.2. Oral Solid Dosage Manufacturing Market in North America: Distribution by Type of Packaging 27.2.1. Oral Solid Dosage Manufacturing Market in North America for Blisters, Forecasted Estimates (Till 2035) 27.2.2. Oral Solid Dosage Manufacturing Market in North America for Bottles, Forecasted Estimates (Till 2035) 27.2.3. Oral Solid Dosage Manufacturing Market in North America for Other Packaging, Forecasted Estimates (Till 2035) 27.3. Oral Solid Dosage Manufacturing Market in North America: Distribution by Type of Release Mechanism 27.3.1. Oral Solid Dosage Manufacturing Market in North America for Immediate Release, Forecasted Estimates (Till 2035) 27.3.2. Oral Solid Dosage Manufacturing Market in North America for Modified Release, Forecasted Estimates (Till 2035) 27.4. Oral Solid Dosage Manufacturing Market in North America: Distribution by Therapeutic Area 27.4.1. Oral Solid Dosage Manufacturing Market in North America for Oncological Disorders, Forecasted Estimates (Till 2035) 27.4 2. Oral Solid Dosage Manufacturing Market in North America for Cardiovascular Disorders, Forecasted Estimates (Till 2035) 27.4.3. Oral Solid Dosage Manufacturing Market in North America for Infectious Diseases, Forecasted Estimates (Till 2035) 27.4.4. Oral Solid Dosage Manufacturing Market in North America for Neurological Disorders, Forecasted Estimates (Till 2035) 27.4.5. Oral Solid Dosage Manufacturing Market in North America for Diabetes, Forecasted Estimates (Till 2035) 27.4.6. Oral Solid Dosage Manufacturing Market in North America for Respiratory Disorders, Forecasted Estimates (Till 2035) 27.4.7. Oral Solid Dosage Manufacturing Market in North America for Immunological Disorders, Forecasted Estimates (Till 2035) 27.4.8. Oral Solid Dosage Manufacturing Market in North America for Genetic Disorders, Forecasted Estimates (Till 2035) 27.4.9. Oral Solid Dosage Manufacturing Market in North America for Rare Diseases, Forecasted Estimates (Till 2035) 27.4.10. Oral Solid Dosage Manufacturing Market in North America for Other Disorders, Forecasted Estimates (Till 2035) 27.5. Oral Solid Dosage Manufacturing Market in North America: Distribution by Company Size 27.5.1. Oral Solid Dosage Manufacturing Market in North America for Small Companies, Forecasted Estimates (Till 2035) 27.5.2. Oral Solid Dosage Manufacturing Market in North America for Mid-Sized Companies, Forecasted Estimates (Till 2035) 27.5.3. Oral Solid Dosage Manufacturing Market in North America for Large Companies, Forecasted Estimates (Till 2035) 28. MARKET FORECAST OPPORTUNITY ANALYSIS: EUROPE 28.1. Oral Solid Dosage Manufacturing Market in Europe: Distribution by Type of Finished Dosage Forms 28.1.1. Oral Solid Dosage Manufacturing Market in Europe for Tablets, Forecasted Estimates (Till 2035) 28.1.2. Oral Solid Dosage Manufacturing Market in Europe for Capsules, Forecasted Estimates (Till 2035) 28.1.3. Oral Solid Dosage Manufacturing Market in Europe for Other Finished Dosage Forms, Forecasted Estimates (Till 2035) 28.2. Oral Solid Dosage Manufacturing Market in Europe: Distribution by Type of Packaging 28.2.1. Oral Solid Dosage Manufacturing Market in Europe for Blisters, Forecasted Estimates (Till 2035) 28.2.2. Oral Solid Dosage Manufacturing Market in Europe for Bottles, Forecasted Estimates (Till 2035) 28.2.3. Oral Solid Dosage Manufacturing Market in Europe for Other Packaging, Forecasted Estimates (Till 2035) 28.3. Oral Solid Dosage Manufacturing Market in Europe: Distribution by Type of Release Mechanism 28.3.1. Oral Solid Dosage Manufacturing Market in Europe for Immediate Release, Forecasted Estimates (Till 2035) 28.3.2. Oral Solid Dosage Manufacturing Market in Europe for Modified Release, Forecasted Estimates (Till 2035) 28.4. Oral Solid Dosage Manufacturing Market in Europe: Distribution by Therapeutic Area 28.4.1. Oral Solid Dosage Manufacturing Market in Europe for Oncological Disorders, Forecasted Estimates (Till 2035) 28.4 2. Oral Solid Dosage Manufacturing Market in Europe for Cardiovascular Disorders, Forecasted Estimates (Till 2035) 28.4.3. Oral Solid Dosage Manufacturing Market in Europe for Infectious Diseases, Forecasted Estimates (Till 2035) 28.4.4. Oral Solid Dosage Manufacturing Market in Europe for Neurological Disorders, Forecasted Estimates (Till 2035) 28.4.5. Oral Solid Dosage Manufacturing Market in Europe for Diabetes, Forecasted Estimates (Till 2035) 28.4.6. Oral Solid Dosage Manufacturing Market in Europe for Respiratory Disorders, Forecasted Estimates (Till 2035) 28.4.7. Oral Solid Dosage Manufacturing Market in Europe for Immunological Disorders, Forecasted Estimates (Till 2035) 28.4.8. Oral Solid Dosage Manufacturing Market in Europe for Genetic Disorders, Forecasted Estimates (Till 2035) 28.4.9. Oral Solid Dosage Manufacturing Market in Europe for Rare Diseases, Forecasted Estimates (Till 2035) 28.4.10. Oral Solid Dosage Manufacturing Market in Europe for Other Disorders, Forecasted Estimates (Till 2035) 28.5. Oral Solid Dosage Manufacturing Market in Europe: Distribution by Company Size 28.5.1. Oral Solid Dosage Manufacturing Market in Europe for Small Companies, Forecasted Estimates (Till 2035) 28.5.2. Oral Solid Dosage Manufacturing Market in Europe for Mid-Sized Companies, Forecasted Estimates (Till 2035) 28.5.3. Oral Solid Dosage Manufacturing Market in Europe for Large Companies, Forecasted Estimates (Till 2035) 29. MARKET FORECAST OPPORTUNITY ANALYSIS: ASIA-PACIFIC 29.1. Oral Solid Dosage Manufacturing Market in Asia-Pacific: Distribution by Type of Finished Dosage Forms 29.1.1. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Tablets, Forecasted Estimates (Till 2035) 29.1.2. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Capsules, Forecasted Estimates (Till 2035) 29.1.3. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Other Finished Dosage Forms, Forecasted Estimates (Till 2035) 29.2. Oral Solid Dosage Manufacturing Market in Asia-Pacific: Distribution by Type of Packaging 29.2.1. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Blisters, Forecasted Estimates (Till 2035) 29.2.2. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Bottles, Forecasted Estimates (Till 2035) 29.2.3. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Other Packaging, Forecasted Estimates (Till 2035) 29.3. Oral Solid Dosage Manufacturing Market in Asia-Pacific: Distribution by Type of Release Mechanism 29.3.1. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Immediate Release, Forecasted Estimates (Till 2035) 29.3.2. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Modified Release, Forecasted Estimates (Till 2035) 29.4. Oral Solid Dosage Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area 29.4.1. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Oncological Disorders, Forecasted Estimates (Till 2035) 29.4 2. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Cardiovascular Disorders, Forecasted Estimates (Till 2035) 29.4.3. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Infectious Diseases, Forecasted Estimates (Till 2035) 29.4.4. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Neurological Disorders, Forecasted Estimates (Till 2035) 29.4.5. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Diabetes, Forecasted Estimates (Till 2035) 29.4.6. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Respiratory Disorders, Forecasted Estimates (Till 2035) 29.4.7. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Immunological Disorders, Forecasted Estimates (Till 2035) 29.4.8. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Genetic Disorders, Forecasted Estimates (Till 2035) 29.4.9. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Rare Diseases, Forecasted Estimates (Till 2035) 29.4.10. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Other Disorders, Forecasted Estimates (Till 2035) 29.5. Oral Solid Dosage Manufacturing Market in Asia-Pacific: Distribution by Company Size 29.5.1. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Small Companies, Forecasted Estimates (Till 2035) 29.5 2. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Mid-Sized Companies, Forecasted Estimates (Till 2035) 29.5.3. Oral Solid Dosage Manufacturing Market in Asia-Pacific for Large Companies, Forecasted Estimates (Till 2035) 30. MARKET FORECAST OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA 30.1. Oral Solid Dosage Manufacturing Market in Middle East and North Africa: Distribution by Type of Finished Dosage Forms 30.1.1. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Tablets, Forecasted Estimates (Till 2035) 30.1.2. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Capsules, Forecasted Estimates (Till 2035) 30.1.3. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Other Finished Dosage Forms, Forecasted Estimates (Till 2035) 30.2. Oral Solid Dosage Manufacturing Market in Middle East and North Africa: Distribution by Type of Packaging 30.2.1. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Blisters, Forecasted Estimates (Till 2035) 30.2.2. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Bottles, Forecasted Estimates (Till 2035) 30.2.3. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Other Packaging, Forecasted Estimates (Till 2035) 30.3. Oral Solid Dosage Manufacturing Market in Middle East and North Africa: Distribution by Type of Release Mechanism 30.3.1. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Immediate Release, Forecasted Estimates (Till 2035) 30.3.2. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Modified Release, Forecasted Estimates (Till 2035) 30.4. Oral Solid Dosage Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area 30.4.1. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Oncological Disorders, Forecasted Estimates (Till 2035) 30.4 2. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Cardiovascular Disorders, Forecasted Estimates (Till 2035) 30.4.3. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Infectious Diseases, Forecasted Estimates (Till 2035) 30.4.4. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Neurological Disorders, Forecasted Estimates (Till 2035) 30.4.5. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Diabetes, Forecasted Estimates (Till 2035) 30.4.6. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Respiratory Disorders, Forecasted Estimates (Till 2035) 30.4.7. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Immunological Disorders, Forecasted Estimates (Till 2035) 30.4.8. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Genetic Disorders, Forecasted Estimates (Till 2035) 30.4.9. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Rare Diseases, Forecasted Estimates (Till 2035) 30.4.10. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Other Disorders, Forecasted Estimates (Till 2035) 30.5. Oral Solid Dosage Manufacturing Market in Middle East and North Africa: Distribution by Company Size 30.5.1. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Small Companies, Forecasted Estimates (Till 2035) 30.5.2. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Mid-Sized Companies, Forecasted Estimates (Till 2035) 30.5.3. Oral Solid Dosage Manufacturing Market in Middle East and North Africa for Large Companies, Forecasted Estimates (Till 2035) 31. MARKET FORECAST OPPORTUNITY ANALYSIS: LATIN AMERICA 31.1. Oral Solid Dosage Manufacturing Market in Latin America: Distribution by Type of Finished Dosage Forms 31.1.1. Oral Solid Dosage Manufacturing Market in Latin America for Tablets, Forecasted Estimates (Till 2035) 31.1.2. Oral Solid Dosage Manufacturing Market in Latin America for Capsules, Forecasted Estimates (Till 2035) 31.1.3. Oral Solid Dosage Manufacturing Market in Latin America for Other Finished Dosage Forms, Forecasted Estimates (Till 2035) 31.2. Oral Solid Dosage Manufacturing Market in Latin America: Distribution by Type of Packaging 31.2.1. Oral Solid Dosage Manufacturing Market in Latin America for Blisters, Forecasted Estimates (Till 2035) 31.2.2. Oral Solid Dosage Manufacturing Market in Latin America for Bottles, Forecasted Estimates (Till 2035) 31.2.3. Oral Solid Dosage Manufacturing Market in Latin America for Other Packaging, Forecasted Estimates (Till 2035) 31.3. Oral Solid Dosage Manufacturing Market in Latin America: Distribution by Type of Release Mechanism 31.3.1. Oral Solid Dosage Manufacturing Market in Latin America for Immediate Release, Forecasted Estimates (Till 2035) 31.3.2. Oral Solid Dosage Manufacturing Market in Latin America for Modified Release, Forecasted Estimates (Till 2035) 31.4. Oral Solid Dosage Manufacturing Market in Latin America: Distribution by Therapeutic Area 31.4.1. Oral Solid Dosage Manufacturing Market in Latin America for Oncological Disorders, Forecasted Estimates (Till 2035) 31.4 2. Oral Solid Dosage Manufacturing Market in Latin America for Cardiovascular Disorders, Forecasted Estimates (Till 2035) 31.4.3. Oral Solid Dosage Manufacturing Market in Latin America for Infectious Diseases, Forecasted Estimates (Till 2035) 31.4.4. Oral Solid Dosage Manufacturing Market in Latin America for Neurological Disorders, Forecasted Estimates (Till 2035) 31.4.5. Oral Solid Dosage Manufacturing Market in Latin America for Diabetes, Forecasted Estimates (Till 2035) 31.4.6. Oral Solid Dosage Manufacturing Market in Latin America for Respiratory Disorders, Forecasted Estimates (Till 2035) 31.4.7. Oral Solid Dosage Manufacturing Market in Latin America for Immunological Disorders, Forecasted Estimates (Till 2035) 31.4.8. Oral Solid Dosage Manufacturing Market in Latin America for Genetic Disorders, Forecasted Estimates (Till 2035) 31.4.9. Oral Solid Dosage Manufacturing Market in Latin America for Rare Diseases, Forecasted Estimates (Till 2035) 31.4.10. Oral Solid Dosage Manufacturing Market in Latin America for Other Disorders, Forecasted Estimates (Till 2035) 31.5. Oral Solid Dosage Manufacturing Market in Latin America: Distribution by Company Size 31.5.1. Oral Solid Dosage Manufacturing Market in Latin America for Small Companies, Forecasted Estimates (Till 2035) 31.5.2. Oral Solid Dosage Manufacturing Market in Latin America for Mid-Sized Companies, Forecasted Estimates (Till 2035) 31.5.3. Oral Solid Dosage Manufacturing Market in Latin America for Large Companies, Forecasted Estimates (Till 2035) 32. EXECUTIVE INSIGHTS 33. CONCLUDING REMARKS 34. APPENDIX 1: TABULATED DATA 35. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

圖表清單 List of Tables & Figures

Table 3.1 Commonly Used Excipients in Tablet Formulation Table 3.1 Contrasting Characteristics: Film-coated and Sugar-coated Tablets Table 3.2 Contrasting Characteristics: Hard Gelatin and Soft Gelatin Capsules Table 4.1 Oral Solid Dosage Contract Manufacturing: List of Companies Table 4.2 Oral Solid Dosage Contract Manufacturers: Information on Services Offered Table 4.3 Oral Solid Dosage Contract Manufacturers: Information on Type of Finished Dosage Form Manufactured Table 4.4 Oral Solid Dosage Contract Manufacturers: Information on Type of Tablets and Capsules Manufactured Table 4.5 Oral Solid Dosage Contract Manufacturers: Information on Type of Multi-particulates Manufactured Table 4.6 Oral Solid Dosage Contract Manufacturers: Information on Type of Primary Packaging Offered Table 4.7 Oral Solid Dosage Contract Manufacturers: Information on Scale of Operation and Additional Manufacturing Capabilities Table 4.8 Oral Solid Dosage Contract Manufacturers: Information on Regulatory Certifications and Accreditations Table 6.1 Oral Solid Dosage Contract Manufacturers based in North America: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities Table 6.2 Oral Solid Dosage Contract Manufacturers based in North America: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities Table 6.3 Oral Solid Dosage Contract Manufacturers based in Europe: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities Table 6.4 Oral Solid Dosage Contract Manufacturers based in Europe: Information Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities Table 6.5 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities Table 6.6 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities Table 7.1 Oral Solid Dosage Contract Manufacturing Service Providers: List of Profiled Companies Table 7.2 Alcami: Company Snapshot Table 7.3 Alcami: Service Portfolio Table 7.4 Alcami: Recent Developments and Future Outlook Table 7.5 Cambrex: Company Snapshot Table 7.6 Cambrex: Service Portfolio Table 7.7 Cambrex: Oral Solid Manufacturing Facilities, Table 7.8 Cambrex: Recent Developments and Future Outlook Table 7.9 Catalent: Company Snapshot Table 7.10 Catalent: Service Portfolio Table 7.11 Catalent: Oral Solid Manufacturing Facilities Table 7.12 Catalent: Recent Developments and Future Outlook Table 7.13 Aenova: Company Snapshot Table 7.14 Aenova: Service Portfolio Table 7.15 Aenova: Oral Solid Manufacturing Facilities Table 7.16 Aenova: Recent Developments and Future Outlook Table 7.17 Almac: Company Snapshot Table 7.18 Almac: Service Portfolio Table 7.19 Almac: Oral Solid Manufacturing Facilities, Table 7.20 Almac: Recent Developments and Future Outlook Table 7.21 Lonza: Company Snapshot Table 7.22 Lonza: Service Portfolio Table 7.23 Lonza: Oral Solid Manufacturing Facilities Table 7.24 Lonza: Recent Developments and Future Outlook Table 7.25 Hetero Drugs: Company Snapshot Table 7.26 Hetero Drugs: Service Portfolio Table 7.27 Hetero Drugs: Recent Developments and Future Outlook Table 7.28 Ind-Swift Laboratories: Company Snapshot Table 7.29 Ind-Swift Laboratories: Service Portfolio Table 7.30 Ind-Swift Laboratories: Oral Solid Manufacturing Facilities Table 7.31 Rubicon Research: Company Snapshot Table 7.32 Rubicon Research: Service Portfolio Table 7.33 Rubicon Research: Oral Solid Manufacturing Facilities Table 9.1 Oral Solid Dosage Contract Manufacturers: List of Recent Expansions, 2018-2022 Table 9.2 Recent Expansions: Information on Type of Oral Solid Dosage Forms Involved, Type of Services Offered and Scales of Operation, 2018-2022 Table 10.1 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Type of Finished Dosage Form): Sample Data Set Table 10.2 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size): Sample Data Set Table 10.3 Distribution by Amount of API in Various Types of Oral Solid Dosage Forms: Sample Data Set Table 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size Table 11.1 Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton) Table 11.2 Demand and Supply Analysis: Information on Annual Capacity Utilization Rates Table 11.3 Annual Outsourced Demand (Base and Optimistic Scenarios): 2023-2035 (Metric Tons) Table 12.1 Total Cost of Ownership: Sample Dataset for CapEx Table 12.2 Total Cost of Ownership: Sample Dataset for OpEx Table 13.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis Table 13.2 Health Canada’s Good Manufacturing Practices Guidelines for Tablets and Capsules Table 13.3 Oral Solid Dosage CMOs: Information on Approval from Various Regulatory Authorities Table 13.4 Key Regulatory Authorities: Comparison of NDA Approval Characteristics Table 14.1 List of Taste Masking and Taste Assessment Service Providers Table 14.2 Taste Masking and Taste Assessment Services: Information on Services Offered, Scale of Operation and Other Services Offered Table 14.3 Taste Masking and Taste Assessment Services: Information on Type of Formulation Table 14.4 Taste Masking and Taste Assessment Services: Information on End Users, Techniques Used for Taste Masking, Branch of Healthcare and Regional Capability Table 15.1 List of Bioavailability Enhancement Service Providers Table 15.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Principle Table 15.3 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approach Table 15.4 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Approaches Table 15.5 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches Table 15.6 Bioavailability Enhancement Service Providers: Information on Lipid-Based Approaches Table 15.7 Bioavailability Enhancement Service Providers: Information on Other Approaches Table 15.8 Bioavailability Enhancement Service Providers: Information on Dosage Form, , Table 15.9 Bioavailability Enhancement Service Providers: Information on Route of Administration Table 17.1 Bushu Pharmaceuticals: Key Highlights Table 19.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment Table 19.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size Table 19.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters Table 19.4 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters (Country-wise) Table 19.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership Table 19.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Services Offered Table 19.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form Table 19.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablets Manufactured Table 19.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsules Manufactured Table 19.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulates Table 19.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered Table 19.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation Table 19.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing Table 19.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing Table 19.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certifications and Accreditations Table 19.16 Catalent: Annual Revenues, FY 2017 – FY 2022 (USD Billion) Table 19.17 Aenova: Annual Revenues, FY 2017 – FY 2021 (EUR Million) Table 19.18 Almac: Annual Revenues, FY 2017 – FY 2021 (GBP Million) Table 19.19 Lonza: Annual Revenues, FY 2017 – FY 2022 (CHF Billion) Table 19.20 Ind-Swift Laboratories: Annual Revenues, FY 2017 – FY 2022 (INR Billion) Table 19.21 Recent Expansions: Cumulative Year-wise Trend, 2018-2022 Table 19.22 Recent Expansions: Distribution by Type of Expansion Table 19.23 Recent Expansions: Distribution by Year and Type of Expansion Table 19.24 Recent Expansions: Distribution by Type of Oral Solid Dosage Forms Involved Table 19.25 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Forms Involved Table 19.26 Recent Expansions: Distribution by Type of Services Offered Table 19.27 Recent Expansion: Distribution by Scale of Operation Table 19.28 Recent Expansions: Distribution by Location of Facility (Region-wise) Table 19.29 Recent Expansions: Distribution by Location of Facility (Country-wise) Table 19.30 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion Table 19.31 Annual Global Capacity for Oral Solid Contract Manufacturing (Number of FDF Units): Distribution by Company Size and Range of Installed Capacity Table 19.32 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Average Weight of Various Finished Dosage Forms): Sample Data Set Table 19.33 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Share of API in Various Finished Dosage Forms): Sample Data Set Table 19.34 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size Table 19.35 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation Table 19.36 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form Table 19.37 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility Table 19.38 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form Table 19.39 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility Table 19.40 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility Table 19.41 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API Processed): Distribution by Company Size Table 19.42 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation Table 19.43 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form Table 19.44 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form Table 19.45 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility Table 19.46 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility Table 19.47 Annual Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons) Table 19.48 Demand Analysis: Annual Demand for Oral Solid Doses, 2023-2035 (Metric Ton) Table 19.49 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton) Table 19.50 Annual Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton) Table 19.51 Commercial Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton) Table 19.52 Commercial Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton) Table 19.53 Commercial Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton) Table 19.54 Commercial Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton) Table 19.55 Commercial Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton) Table 19.56 Commercial Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton) Table 19.57 Commercial Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton) Table 19.58 Commercial Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton) Table 19.59 Commercial Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton) Table 19.60 Commercial Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton) Table 19.61 Commercial Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton) Table 19.62 Commercial Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton) Table 19.63 Commercial Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton) Table 19.64 Commercial Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton) Table 19.65 Annual Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton) Table 19.66 Clinical Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton) Table 19.67 Clinical Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton) Table 19.68 Clinical Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton) Table 19.69 Clinical Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton) Table 19.70 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million) Table 19.71 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million) Table 19.72 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million) Table 19.73 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million) Table 19.74 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million) Table 19.75 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment Table 19.76 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size Table 19.77 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters Table 19.78 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters Table 19.79 Taste Masking and Taste Assessment Services: Distribution by Services Offered Table 19.80 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation Table 19.81 Taste Masking and Taste Assessment Services: Distribution by Other Services Offered Table 19.82 Taste Masking and Taste Assessment Services: Distribution by Type of Formulations Table 19.83 Taste Masking and Taste Assessment Services: Distribution by End Users Table 19.84 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking Table 19.85 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare Table 19.86 Taste Masking and Taste Assessment Services: Distribution by Regional Capability Table 19.87 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment Table 19.88 Bioavailability Enhancement Service Providers: Distribution by Company Size Table 19.89 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region-wise) Table 19.90 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise) Table 19.91 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle Table 19.92 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach Table 19.93 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches Table 19.94 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches Table 19.95 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches Table 19.96 Bioavailability Enhancement Service Providers: Distribution by Other Approaches Table 19.97 Bioavailability Enhancement Service Providers: Distribution by Dosage Form Table 19.98 Bioavailability Enhancement Service Providers: Distribution by Route of Administration Table 19.99 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion) Table 19.100 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form Table 19.101 Tablet Manufacturing Market, 2023-2035 (USD Billion) Table 19.102 Capsule Manufacturing Market, 2023-2035 (USD Billion) Table 19.103 Powder Manufacturing Market, 2023-2035 (USD Billion) Table 19.104 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion) Table 19.105 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion) Table 19.106 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging Table 19.107 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion) Table 19.108 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion) Table 19.109 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion) Table 19.110 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion) Table 19.111 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion) Table 19.112 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion) Table 19.113 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation Table 19.114 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion) Table 19.115 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion) Table 19.116 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size Table 19.117 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion) Table 19.118 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion) Table 19.119 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion) Table 19.120 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion) Table 19.121 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area Table 19.122 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion) Table 19.123 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion) Table 19.124 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion) Table 19.125 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion) Table 19.126 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion) Table 19.127 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion) Table 19.128 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion) Table 19.129 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion) Table 19.130 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion) Table 19.131 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Geographical Regions (USD Billion) Table 19.132 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion) Table 19.133 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion) Table 19.134 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion) Table 19.135 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion) Table 19.136 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion) Figure 2.1 Executive Summary: Market Landscape Figure 2.2 Executive Summary: Services Landscape Figure 2.3 Executive Summary: Recent Expansions Figure 2.4 Executive Summary: Capacity Analysis Figure 2.5 Executive Summary: Demand Analysis Figure 2.6 Executive Summary: Total Cost of Ownership Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis Figure 2.8 Executive Summary: Case Study on Taste Masking Service Providers Figure 2.9 Executive Summary: Case Study on Bioavailability Enhancement Service Providers Figure 3.1 Properties of Dosage Forms Figure 3.2 Types of Dosage Forms Figure 3.3 Advantages and Disadvantages of Oral Solid Dosage Forms Figure 3.4 Properties of Pharmaceutical Excipient Figure 3.5 Type of Oral Solid Dosage Forms Figure 3.6 Classification of Orally Administered Tablets Figure 3.7 Tablet Processing Methods Figure 3.8 Oral Solid Dosage Manufacturing Process Figure 3.9 Services Offered by CDMOs and CMOs for Oral Solid Dosage Figure 3.10 Key Considerations While Selecting a CDMO or CMO Partner Figure 4.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment Figure 4.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size Figure 4.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters Figure 4.4 World Map Representation: Distribution by Geography Figure 4.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership Figure 4.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Services Offered Figure 4.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form Figure 4.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablets Manufactured Figure 4.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsules Manufactured Figure 4.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulates Manufactured Figure 4.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered Figure 4.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation Figure 4.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing Figure 4.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing Figure 4.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certification / Accreditation Figure 5.1 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in the US Figure 5.2 Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Canada Figure 5.3 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in the EU5 Figure 5.4 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Other European Countries Figure 5.5 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in India Figure 5.6 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in China Figure 5.7 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Japan Figure 5.8 Company Competitiveness Analysis: Oral Solid Contract Manufacturers Based in Other Asia-Pacific and Rest of the World Figure 5.9 Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers Figure 6.1 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Manufacturing Facilities Figure 6.2 Oral Solid Dosage Contract Manufacturing: North America Scenario (I / II) Figure 6.3 Oral Solid Dosage Contract Manufacturers: North America Scenario (II / II) Figure 6.4 Oral Solid Dosage Contract Manufacturing: Europe Scenario (I / II) Figure 6.5 Oral Solid Dosage Contract Manufacturers: Europe Scenario (II / II) Figure 6.6 Oral Solid Dosage Contract Manufacturing: Asia-Pacific and Rest of the World Scenario (I / II) Figure 6.7 Oral Solid Dosage Contract Manufacturers: Asia-Pacific and Rest of the World Scenario (II / II) Figure 7.1 Catalent: Annual Revenues, FY 2017- FY 2022 (USD Billion) Figure 7.2 Catalent: Distribution of FY 2022 Revenues by Business Segment Figure 7.3 Aenova: Annual Revenues, FY 2017- FY 2021 (EUR Million) Figure 7.4 Aenova: Distribution of FY 2021 Revenues by Type of Business Segment Figure 7.5 Almac: Annual Revenues, FY 2017- FY 2021 (GBP Million) Figure 7.6 Lonza: Annual Revenues, FY 2017- FY 2022 (CHF Billion) Figure 7.7 Lonza: Distribution of FY 2022 Revenues by Type of Business Segment Figure 7.8 Ind-Swift Laboratories: Annual Revenues, FY 2017- FY 2022 (INR Billion) Figure 8.1 Make versus Buy Decision Making Framework Figure 8.2 Make versus Buy Decision Making: Possible Scenario Descriptions Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2018-2022 Figure 9.2 Recent Expansions: Distribution by Type of Expansion Figure 9.3 Recent Expansions: Distribution by Year and Type of Expansion Figure 9.4 Recent Expansions: Distribution by Type of Oral Solid Dosage Forms Involved Figure 9.5 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Forms Involved Figure 9.6 Recent Expansions: Distribution by Type of Services Offered Figure 9.7 Recent Expansion: Distribution by Scale of Operation Figure 9.8 Recent Expansions: Distribution by Location of Facility (Region-wise) Figure 9.9 Recent Expansions: Distribution by Location of Facility (Country-wise) Figure 9.10 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion Figure 10.1 Annual Minimum, Average and Maximum Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size: Sample Data Set Figure 10.2 Distribution by Minimum, Average and Maximum Weight of Various Finished Dosage Forms: Sample Data Set Figure 10.3 Distribution by Minimum, Average and Maximum Share of API in Various Finished Dosage Forms: Sample Data Set Figure 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size Figure 10.5 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation Figure 10.6 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form Figure 10.7 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility Figure 10.8 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form Figure 10.9 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility Figure 10.10 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility Figure 10.11 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size Figure 10.12 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Amount of API): Distribution by Scale of Operation Figure 10.13 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form Figure 10.14 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form Figure 10.15 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility Figure 10.16 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility Figure 11.1 Demand Analysis: Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton) Figure 11.2 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton) Figure 11.3 Annual Outsourced Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton) Figure 11.4 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton) Figure 11.5 Commercial Outsourced Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton) Figure 11.6 Commercial Outsourced Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton) Figure 11.7 Commercial Outsourced Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton) Figure 11.8 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton) Figure 11.9 Commercial Outsourced Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton) Figure 11.10 Commercial Outsourced Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton) Figure 11.11 Commercial Outsourced Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton) Figure 11.12 Commercial Outsourced Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton) Figure 11.13 Commercial Outsourced Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton) Figure 11.14 Commercial Outsourced Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton) Figure 11.15 Commercial Outsourced Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton) Figure 11.16 Commercial Outsourced Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton) Figure 11.17 Commercial Outsourced Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton) Figure 11.18 Annual Outsourced Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton) Figure 11.19 Clinical Outsourced Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton) Figure 11.20 Clinical Outsourced Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton) Figure 11.21 Clinical Outsourced Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton) Figure 11.22 Clinical Outsourced Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton) Figure 11.23 Annual Outsourced Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons) Figure 11.24 Oral Solid Dosage Contract Manufacturing: Correlation between Demand and Capacity, 2023-2035 Figure 12.1 Total Cost of Ownership: Types of Capital Expenditures (CapEx) Figure 12.2 Total Cost of Ownership: Types of Operational Expenditures (OpEx) Figure 12.3 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million) Figure 12.4 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million) Figure 12.5 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million) Figure 12.6 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million) Figure 12.7 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million) Figure 13.1 Key Regulatory Requirements for CMOs and CROs in India Figure 13.2 Regulatory Landscape for Oral Solid Dosage CMOs: Distribution by Certifications / Accreditations Received Figure 13.3 Bubble Analysis: Regional Regulatory Summary Figure 14.1 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment Figure 14.2 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size Figure 14.3 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters Figure 14.4 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters Figure 14.5 Taste Masking and Taste Assessment Services: Distribution by Services Offered Figure 14.6 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation Figure 14.7 Taste Masking and Taste Assessment Services: Distribution by Other Services Offered Figure 14.8 Taste Masking and Taste Assessment Services: Distribution by Type of Formulations Figure 14.9 Taste Masking and Taste Assessment Services: Distribution by End Users Figure 14.10 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking Figure 14.11 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare Figure 14.12 Taste Masking and Taste Assessment Services: Distribution by Regional Capability Figure 15.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment Figure 15.2 Bioavailability Enhancement Service Providers: Distribution by Company Size Figure 15.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise) Figure 15.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise) Figure 15.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle Figure 15.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach Figure 15.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches Figure 15.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches Figure 15.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches Figure 15.10 Bioavailability Enhancement Service Providers: Distribution by Other Approaches Figure 15.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form Figure 15.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration Figure 16.1 Oral Solid Dosage Contract Manufacturing: Market Forecast Approach Figure 16.2 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion) Figure 16.3 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form Figure 16.4 Tablet Manufacturing Market, 2023-2035 (USD Billion) Figure 16.5 Capsule Manufacturing Market, 2023-2035 (USD Billion) Figure 16.6 Powder Manufacturing Market, 2023-2035 (USD Billion) Figure 16.7 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion) Figure 16.8 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion) Figure 16.9 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging (USD Billion) Figure 16.10 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion) Figure 16.11 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion) Figure 16.12 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion) Figure 16.13 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion) Figure 16.14 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion) Figure 16.15 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion) Figure 16.16 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation (USD Billion) Figure 16.17 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion) Figure 16.18 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion) Figure 16.19 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size (USD Billion) Figure 16.20 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion) Figure 16.21 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion) Figure 16.22 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion) Figure 16.23 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion) Figure 16.24 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area (USD Billion) Figure 16.25 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion) Figure 16.26 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion) Figure 16.27 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion) Figure 16.28 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion) Figure 16.29 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion) Figure 16.30 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion) Figure 16.31 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion) Figure 16.32 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion) Figure 16.33 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion) Figure 16.34 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Key Geographical Regions (USD Billion) Figure 16.35 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion) Figure 16.36 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion) Figure 16.37 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion) Figure 16.38 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion) Figure 16.39 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion)

提及公司

Aar BiosysAaschem Life CareAavis PharmaceuticalsAbbVieAbbVie Contract ManufacturingAbiogen PharmaABITECAccu-Break PharmaceuticalsAcenziaACIC PharmaceuticalsAcinoAcme GroupACS DobfarActiza PharmaceuticalAdare Pharma SolutionsAdept PharmaAdipharmAenovaAfriplexAiomedic PharmaceuticalsAiPing PharmaceuticalAizant Drug Research SolutionsAjinomoto Bio-Pharma ServicesAkrikhinAKRIKHIN (subsidiary of Polpharma)Akums Drugs & PharmaceuticalsAlaron ProductsAlban PharmaAlbia BiocareAlbyPharma

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們